Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Equity (2020 - 2025)

Historic Return on Equity for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to 0.16%.

  • Apellis Pharmaceuticals' Return on Equity rose 11600.0% to 0.16% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.16%, marking a year-over-year increase of 11600.0%. This contributed to the annual value of 0.94% for FY2024, which is 19700.0% up from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Return on Equity is 0.16%, which was up 11600.0% from 1.42% recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Return on Equity registered a high of 46.97% during Q3 2022, and its lowest value of 10.56% during Q4 2021.
  • In the last 5 years, Apellis Pharmaceuticals' Return on Equity had a median value of 1.73% in 2023 and averaged 0.91%.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Return on Equity surged by 421600bps in 2022, and later plummeted by -490700bps in 2023.
  • Apellis Pharmaceuticals' Return on Equity (Quarter) stood at 10.56% in 2021, then soared by 74bps to 2.73% in 2022, then increased by 9bps to 2.48% in 2023, then skyrocketed by 66bps to 0.85% in 2024, then soared by 119bps to 0.16% in 2025.
  • Its Return on Equity stands at 0.16% for Q3 2025, versus 1.42% for Q2 2025 and 1.14% for Q1 2025.